Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namodenoson Phase 2b Study in NASH
2021-005245-32Phase 2Active
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Namodenoson with Placebo (2 arms). Primary endpoint: Histologic improvement in NAFLD activity score. Started May 2023; status: active.
02
Drugs
namodenoson
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2021-005245-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005245-32.